Are PBMs Bad For Your Health?
Executive Summary
All these years, drug companies thought they were the big losers in the growing influence of pharmacy benefit managers (PBMs). They saw prices erode and profits decline as a result of aggressive rebate contracting and generic substitution. The winners were consumers and payers who got more efficient care and relief from the high drug prices.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.